Eylea

Pharma

Biosimilar competiton takes big bite out of Bayer's Eylea sales

Bayer is getting hit with full force by biosimilar competition for its eye disease treatment Eylea, which saw a 24% sales decline in the first quarter.

Kevin Dunleavy May 12, 2026 10:51am

Regeneron sees more regulatory issues, sales declines for Eylea

Apr 29, 2026 12:05pm

Bayer found to have discredited industry after Roche row

Mar 13, 2026 11:45am

Bayer's pharma division sees one more year of declining sales

Mar 4, 2026 11:35am

Ocular's ophthalmologic version of Inlyta bests Eylea in ph. 3

Feb 17, 2026 12:15pm

Regeneron faces category headwinds for eye disease drug Eylea

Jan 30, 2026 11:41am